Taxis Pharmaceuticals Overview

  • Founded
  • 2009
Founded
  • Status
  • Private
  • Employees
  • 14
Employees
  • Latest Deal Type
  • Later Stage VC
  • (Upcoming)
  • Latest Deal Amount
  • $2.5M
Latest Deal Amount
  • Investors
  • 3

Taxis Pharmaceuticals General Information

Description

Developer of antibiotics and antiviral drugs designed to address the health crisis of antimicrobial resistance. The company offers antibiotics and therapeutic agents that employ novel mechanisms of action distinct from those currently in clinical use and target multidrug-resistant bacterial pathogens, thereby enabling hospitals to treat MRSA (Methicillin-Resistant Staphylococcus Aureus) affected patients effectively.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Primary Office
  • 9 Deerpark Drive
  • Monmouth Junction, NJ 08852
  • United States

Taxis Pharmaceuticals Timeline

2018201920202021
Financing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Taxis Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC $2.5M Upcoming Generating Revenue
7. Grant 14-Jan-2020 00.00 000.00 Completed Generating Revenue
6. Later Stage VC 09-Jan-2019 00.000 000.00 Completed Generating Revenue
5. Angel (individual) 25-Sep-2017 000 Cancelled Generating Revenue
4. Later Stage VC (Series B2) 10-Mar-2017 00.00 000.00 Completed Generating Revenue
3. Angel (individual) 22-Jul-2015 000 00.000 000.00 Completed Generating Revenue
2. Angel (individual) 13-Apr-2015 $6.5M $6.74M 0000 Completed Generating Revenue
1. Angel (individual) 19-Apr-2010 $237K $237K Completed Startup
To view Taxis Pharmaceuticals’s complete valuation and funding history, request access »

Taxis Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00
Series A 00,000,000 00.000000 00.00 00.00 00 00.00 00.000
To view Taxis Pharmaceuticals’s complete cap table history, request access »

Taxis Pharmaceuticals Executive Team (4)

Name Title Board Seat Contact Info
Gregory Mario Co-Founder, Chief Executive Officer, President and Board Member
Daniel Pilch Ph.D Co-Founder
Henry Chambers MD Scientific Advisor
Edmond LaVoie Ph.D Co-Founder and Board Member
To view Taxis Pharmaceuticals’s complete executive team members history, request access »

Taxis Pharmaceuticals Board Members (7)

Name Representing Role Since
Christopher Cimarusti Taxis Pharmaceuticals Board Member 000 0000
Edmond LaVoie Ph.D Self Co-Founder and Board Member 000 0000
Ernest Mario Ph.D Taxis Pharmaceuticals Board Member 000 0000
Gail McIntyre Ph.D Self Board Member 000 0000
Gregory Mario Taxis Pharmaceuticals Co-Founder, Chief Executive Officer, President and Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Taxis Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Taxis Pharmaceuticals Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CARB-X University 000 0000 000000 0
Eagles Ketch Asset Manager Minority 000 0000 000000 0
Ithaka Partners Growth/Expansion Minority 000 0000 000000 0
To view Taxis Pharmaceuticals’s complete investors history, request access »